Homepage Top Section2

The partnership will bring together Voro Therapeutics’ tumour-activated biologics platform with Alloy Therapeutics’ cluster of differentiation 3 (CD3) antibodies and multispecific engineering capabilities. This joint effort aims to

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within

The agreement broadens AviadoBio’s existing rights, which were previously limited to the development of gene therapies for neurological diseases under a 2020 agreement. The vMiX platform leverages adeno-associated

The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy. In the US, the ODD offers incentives such as tax

Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field. If the research is successful, Simcere will have the

The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Study results showed that gumokimab delivered rapid and strong efficacy.

The collaboration follows a successful pilot phase, where XtalPi’s integrated quantum physics and AI algorithms achieved improved hit rates, highlighting the platform’s capability to address the complex metabolic target.

Upon completion of the transaction, Ignite will separate from Aditxt and is expected to become an independent public company via the establishment of a new holding entity, anticipated

The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery and development. Since 2021, Sanofi and Owkin have maintained a